These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 28923250)
1. Assessing the potential role of next generation tyrosine kinase inhibitors in the treatment of cancers with acquired kinase domain mutations. Thirumal Raj A; Patil S; Ranadheer R; Chandini R Oral Oncol; 2017 Oct; 73():172. PubMed ID: 28923250 [No Abstract] [Full Text] [Related]
2. Heritable resistance to tyrosine kinase inhibitors. Ong ST Clin Adv Hematol Oncol; 2014 Jul; 12(7):454-7. PubMed ID: 25322326 [No Abstract] [Full Text] [Related]
3. [Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses]. Joensuu H Duodecim; 2012; 128(21):2261-8. PubMed ID: 23210289 [TBL] [Abstract][Full Text] [Related]
4. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Engelman JA; Settleman J Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754 [TBL] [Abstract][Full Text] [Related]
5. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients. Wongboonma W; Thongnoppakhun W; Auewarakul CU Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255 [TBL] [Abstract][Full Text] [Related]
7. Larotrectinib followed by selitrectinib in a novel Goh XN; Seng MS; Loh AHP; Gupta A; Chang KTE; Iyer P J Oncol Pharm Pract; 2021 Mar; 27(2):485-489. PubMed ID: 32693686 [TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinases as targets for cancer therapy. Krause DS; Van Etten RA N Engl J Med; 2005 Jul; 353(2):172-87. PubMed ID: 16014887 [No Abstract] [Full Text] [Related]
9. Best Use of the Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer: Discussion. Tuttle RM; Brose MS Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):12-3. PubMed ID: 27168343 [No Abstract] [Full Text] [Related]
10. The second generation of BCR-ABL tyrosine kinase inhibitors. Tauchi T; Ohyashiki K Int J Hematol; 2006 May; 83(4):294-300. PubMed ID: 16757427 [TBL] [Abstract][Full Text] [Related]
11. [Protein tyrosine kinase inhibitors in cancer therapy]. Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095 [TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Sierra JR; Cepero V; Giordano S Mol Cancer; 2010 Apr; 9():75. PubMed ID: 20385023 [TBL] [Abstract][Full Text] [Related]
15. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263 [TBL] [Abstract][Full Text] [Related]
16. Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors. Hochhaus A Ann Oncol; 2006 Sep; 17 Suppl 10():x274-9. PubMed ID: 17018738 [No Abstract] [Full Text] [Related]
17. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Daver N; Cortes J; Ravandi F; Patel KP; Burger JA; Konopleva M; Kantarjian H Blood; 2015 May; 125(21):3236-45. PubMed ID: 25795921 [TBL] [Abstract][Full Text] [Related]
18. Overcoming the drug resistance problem with second-generation tyrosine kinase inhibitors: from enzymology to structural models. Crespan E; Zucca E; Maga G Curr Med Chem; 2011; 18(19):2836-47. PubMed ID: 21651495 [TBL] [Abstract][Full Text] [Related]
19. Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases. van der Kuip H; Wohlbold L; Oetzel C; Schwab M; Aulitzky WE Am J Pharmacogenomics; 2005; 5(2):101-12. PubMed ID: 15813673 [TBL] [Abstract][Full Text] [Related]